AI Article Synopsis
- - This study aimed to assess whether getting vaccinated with mRNA COVID-19 vaccines during pregnancy affects the risk of adverse pregnancy outcomes like preterm birth and small-for-gestational age infants.
- - Researchers analyzed data from over 55,000 individuals with live singleton pregnancies and found that 42.3% received one or two doses of the vaccine, with the vaccination rate varying across maternal demographics.
- - The results indicated that vaccinated individuals had a lower risk of preterm birth compared to unvaccinated individuals, but the vaccination did not significantly impact the risks of small-for-gestational age infants, gestational diabetes, gestational hypertension, or preeclampsia.
Article Abstract
Objective: To evaluate the association between antenatal messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccination and risk of adverse pregnancy outcomes.
Methods: This was a retrospective cohort study of individuals with singleton pregnancies with live deliveries between June 1, 2021, and January 31, 2022, with data available from eight integrated health care systems in the Vaccine Safety Datalink. Vaccine exposure was defined as receipt of one or two mRNA COVID-19 vaccine doses (primary series) during pregnancy. Outcomes were preterm birth (PTB) before 37 weeks of gestation, small-for-gestational age (SGA) neonates, gestational diabetes mellitus (GDM), gestational hypertension, and preeclampsia-eclampsia-HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Outcomes in individuals vaccinated were compared with those in propensity-matched individuals with unexposed pregnancies. Adjusted hazard ratios (aHRs) and 95% CIs were estimated for PTB and SGA using a time-dependent covariate Cox model, and adjusted relative risks (aRRs) were estimated for GDM, gestational hypertension, and preeclampsia-eclampsia-HELLP syndrome using Poisson regression with robust variance.
Results: Among 55,591 individuals eligible for inclusion, 23,517 (42.3%) received one or two mRNA COVID-19 vaccine doses during pregnancy. Receipt of mRNA COVID-19 vaccination varied by maternal age, race, Hispanic ethnicity, and history of COVID-19. Compared with no vaccination, mRNA COVID-19 vaccination was associated with a decreased risk of PTB (rate: 6.4 [vaccinated] vs 7.7 [unvaccinated] per 100, aHR 0.89; 95% CI, 0.83-0.94). Messenger RNA COVID-19 vaccination was not associated with SGA (8.3 vs 7.4 per 100; aHR 1.06, 95% CI, 0.99-1.13), GDM (11.9 vs 10.6 per 100; aRR 1.00, 95% CI, 0.90-1.10), gestational hypertension (10.8 vs 9.9 per 100; aRR 1.08, 95% CI, 0.96-1.22), or preeclampsia-eclampsia-HELLP syndrome (8.9 vs 8.4 per 100; aRR 1.10, 95% CI, 0.97-1.24).
Conclusion: Receipt of an mRNA COVID-19 vaccine during pregnancy was not associated with an increased risk of adverse pregnancy outcomes; this information will be helpful for patients and clinicians when considering COVID-19 vaccination in pregnancy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090513 | PMC |
| http://dx.doi.org/10.1097/AOG.0000000000005583 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Occupational-related risk of testing SARS-CoV-2 positive for publicly employed medical doctors in Sweden: A nationwide cohort study.
Scand J Public Health
December 2024
Department of Clinical Microbiology, Umeå University, Sweden.
Aims: Doctors have an increased risk of SARS-CoV-2 infection caused by exposure to contagious patients. We aimed to identify which clinical specialities among medical doctors had the highest occupation-related risk of testing positive for SARS-CoV-2, utilizing data for all publicly employed medical doctors in Sweden.
Methods: Data regarding positive SARS-CoV-2 test results and employment for publicly employed doctors in Sweden were divided into three observation periods: 1) 1 February to 31 December 2020, 2) 1 January to 30 June 2021 and 3) 1 July 2021 to 31 March 2022.
Tortured confessions? Potentially erroneous statistical inferences may underpin misleading claims of harms in reanalyses of COVID-19 and HPV vaccines.
Vaccine
December 2024
TCD Biostatistics Unit, Discipline of Public Health and Primary Care, School of Medicine, Trinity College Dublin, Dublin, Ireland. Electronic address:
The safety and efficacy of vaccination is a subject contentious in the public mind. Despite overwhelming evidence of their benefits to public health, COVID-19 and human papilloma virus (HPV) vaccines have been the focus of intense concerns. While the original phase III trials and post-market phase IV studies have continued to show their benefits and positive safety profile, some authors have attempted to reassess the original trial data, purporting to showing hidden harms for both COVID-19 and HPV vaccines.
View Article and Find Full Text PDFGenomic epidemiology and evolution of under the vaccination pressure of acellular vaccines in Beijing, China, 2020-2023.
Emerg Microbes Infect
December 2024
Beijing Chaoyang District Center for Disease Control and Prevention, Beijing 100021, China.
Pertussis (or whooping cough) has experienced a global resurgence despite widespread vaccine efforts. In China, the incidence of pertussis has rapidly increased, particularly following the COVID-19 pandemic. Whole-genome sequencing analysis was performed on 60 strains isolated in Beijing from 2020 to 2023, and the sequences were compared with those of 635 strains from China and 943 strains from other countries.
View Article and Find Full Text PDFAssociation between immunosuppressive medications and COVID-19 hospitalisation and death: a retrospective cohort study.
BMJ Open
December 2024
Francis I Proctor Foundation for Research in Ophthalmology, San Francisco, California, USA
Importance: Immunocompromised status is a risk factor for severe SARS-CoV-2 infection. Little is known about how systemic corticosteroid dose and concurrent use of immunosuppressants are associated with COVID-19 outcomes.
Objective: To assess the association between corticosteroid dose/duration and concurrent immunosuppressant use on COVID-19 hospitalisation and death in the era of COVID-19 vaccinations.
Update on inborn errors of immunity.
J Allergy Clin Immunol
December 2024
Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia; Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia; Jeffrey Modell Center, Melbourne, Victoria, Australia; Erasmus MC, University Medical Center, Department of Immunology, Rotterdam, the Netherlands. Electronic address:
Ever since the first description of an inherited immunodeficiency in 1952 in a boy with gammaglobulin deficiency, new insights have progressed rapidly in disorders that are now referred to as inborn errors of immunity (IEI). In a field where fundamental molecular biology, genetics, immune signaling and clinical care are tightly intertwined, 2022-2024 saw a multitude of advances. Here we report a selection of research updates with a main focus on (1) diagnosis and screening, (2) new genetic defects, (3) susceptibility to severe COVID-19 infection and impact of vaccination, and (4) treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!